Research progress on the intervention of human umbilical cord mesenchymal stem cell in neurodegenerative disease
- VernacularTitle:人脐带间充质干细胞干预神经退行性变性疾病的研究进展
- Author:
Hongcai XU
1
;
Yumin XU
2
;
Shiyu LIU
1
;
Huayu YAN
1
;
Yuan LIU
1
;
Xin YANG
1
;
Yabo WU
3
Author Information
1. Dept. of Encephalopathy，the First Affiliated Hospital of Henan University of Chinese Medicine，Zhengzhou 451200，China;First Clinical Medical College，Henan University of Chinese Medicine，Zhengzhou 450046，China
2. Dept. of Encephalopathy，the First Affiliated Hospital of Henan University of Chinese Medicine，Zhengzhou 451200，China;First Clinical Medical College，Henan University of Chinese Medicine，Zhengzhou 450046，China;Collaborative Innovation Center of Traditional Chinese and Western Medicine for Prevention and Treatment of Major Diseases in Henan Province，Zhengzhou 451200，China
3. Dept. of Encephalopathy，the First Affiliated Hospital of Henan University of Chinese Medicine，Zhengzhou 451200，China
- Publication Type:Journal Article
- Keywords:
human umbilical cord mesenchymal stem cell;
neurodegenerative disease;
Alzheimer disease;
Parkinson’s disease
- From:
China Pharmacy
2026;37(3):395-400
- CountryChina
- Language:Chinese
-
Abstract:
Human umbilical cord mesenchymal stem cell （hUC-MSC） as a cell-based therapeutic strategy have demonstrated significant application potential in the field of intervention for neurodegenerative disease （NDD） due to their advantages such as self-renewal， multi-directional differentiation， and low immunogenicity. hUC-MSC effectively intervenes in the pathological features and neurological functions of various disease models such as Alzheimer disease， Parkinson’s disease， amyotrophic lateral sclerosis， and multiple sclerosis primarily through multiple mechanisms such as homing and differentiation， mediating paracrine actions and releasing exosomes， as well as immune regulation and anti-inflammation. Some clinical studies have also preliminarily verified their safety and effectiveness. Currently， its research still faces challenges such as immune rejection reactions requiring further observation， long-term safety needing evaluation， mechanisms of action not being fully elucidated， and slow progress in clinical trials. Future research needs to establish pharmaceutical standards for hUC-MSC， deepen their pharmacological mechanisms and clinical trials， ultimately providing new and effective drug treatment options for patients with NDD.
